성인 악성 신경교종 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 9.4%의 CAGR로 35억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 면역요법의 발전, 표적 치료, 바이오마커의 발견, 액체 생검의 적용, 접근성 확대 프로그램 등에 기인합니다. 예측 기간의 주요 동향으로는 환자 중심 의약품 개발, 패스트트랙 및 혁신 신약 지정, 약물전달 시스템의 발전, 공동 연구 이니셔티브, 인공지능의 통합 등이 있습니다.
뇌종양 환자의 증가 추세는 성인 악성 신경교종 치료제 시장의 성장을 촉진하는 중요한 요인이 될 것으로 예측됩니다. 뇌종양은 정상적인 조절 메커니즘을 회피한 세포의 비정상적인 증식과 무제한 성장을 특징으로 하는 비정상적인 조직 덩어리입니다. 성인 악성 신경교종은 비정상적이고 통제할 수 없는 증식 패턴을 보이는 세포로 구성된 특정 유형의 뇌종양입니다. 성인 악성 신경교종 치료는 일반적으로 수술, 방사선 치료, 화학요법을 병행합니다. 미국 암 협회의 2023년 1월 보고서에 따르면, 이러한 추세를 보여주는 뇌 및 신경계 암 관련 사례는 2023년 24,810건으로 2020년 23,890건에서 3.85% 증가하였다고 합니다. 이처럼 뇌종양의 증가는 성인 악성 신경교종 치료제 시장 확대의 원동력이 되고 있습니다.
뇌종양 연구에 특화된 정부 자금 투입은 성인 악성 신경교종 치료제 시장의 성장 궤도를 크게 앞당길 것으로 보입니다. 정부 자금은 연방, 주, 지방 등 다양한 수준의 정부 기관이 이니셔티브, 프로그램, 프로젝트, 조직, 개인에 대해 지출하는 재정적 지원을 의미합니다. 뇌종양 연구에 대한 정부 자금의 배분은 성인 악성 신경교종 치료제를 발전시킬 수 있는 큰 잠재력을 가지고 있습니다. 이 자금은 혁신적인 치료법 개발, 피리미딘 합성을 중심으로 한 맞춤형 약물 설계, 희귀질환 치료제의 신속한 승인에 큰 도움이 될 것입니다. 예를 들어, 2023년 6월 호주 보건 및 노인의료부는 호주 뇌종양 미션(Australian Brain Cancer Mission)을 시작했으며, 특히 뇌종양 연구 활동을 지원하기 위해 1억 3,666만 달러의 기금을 기부했습니다. 이 이니셔티브의 주요 목표는 역형성 성상세포종을 포함한 뇌종양 환자의 생존율을 두 배로 늘리고 전반적인 삶의 질을 향상시키는 것입니다. 결과적으로, 뇌종양 연구를 위한 정부의 자금 지원은 성인 악성 신경교종 치료제 시장을 촉진하는 매우 중요한 요인으로 작용하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 성인 악성 신경교종 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
- 최종 이용 산업 분석
- 세계의 성인 악성 신경교종 치료제 시장 : 성장률 분석
- 세계의 성인 악성 신경교종 치료제 시장 실적 : 규모와 성장, 2019-2024
- 세계의 성인 악성 신경교종 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 성인 악성 신경교종 치료제 전체 시장(TAM)
제6장 시장 세분화
- 세계의 성인 악성 신경교종 치료제 시장 질병 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 다형성교모세포종
- 미분화 성상세포종
- 미분화핍돌기교종
- 미분화핍돌기 성상세포종
- 기타 유형
- 세계의 성인 악성 신경교종 치료제 시장 테라피에 의해 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 화학요법
- 표적요법
- 방사선 치료
- 기타 치료법
- 세계의 성인 악성 신경교종 치료제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 전문 클리닉
- 암·방사선 치료 센터
- 기타 최종사용자
- 세계의 성인 악성 신경교종 치료제 시장 다형성교모세포종 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 표준적치료법
- 실험적 치료법
- 세계의 성인 악성 신경교종 치료제 시장, 미분화 성상세포종 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 화학요법 선택사항
- 표적요법
- 세계의 성인 악성 신경교종 치료제 시장, 미분화 오리고덴드로그리오마 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 방사선 치료
- 병용요법
- 세계의 성인 악성 신경교종 치료제 시장, 미분화핍돌기 성상세포종 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 외과적 개입
- 보조 요법
- 세계의 성인 악성 신경교종 치료제 시장, 기타 유형 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 희귀한 신경교종
- 새로운 치료법
제7장 지역별·국가별 분석
- 세계의 성인 악성 신경교종 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 성인 악성 신경교종 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 성인 악성 신경교종 치료제 시장 : 경쟁 구도
- 성인 악성 신경교종 치료제 시장 : 기업 개요
- Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
- F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- Allergan plc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- AbbVie Inc.
- Novartis AG
- Bayer AG
- Merck & Co Inc.
- GlaxoSmithKline plc
- Bristol-Myers Squibb Company
- Abbott Laboratories
- AstraZeneca plc
- Eli Lilly and Company
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- GT Medical Technologies Inc.
- Lupin Limited
- Mylan NV
- Sanofi SA
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 성인 악성 신경교종 치료제 시장 2029 : 새로운 기회를 제공하는 국가
- 성인 악성 신경교종 치료제 시장 2029 : 새로운 기회를 제공하는 부문
- 성인 악성 신경교종 치료제 시장 2029 : 성장 전략
제36장 부록
ksm
The field of adult malignant glioma therapeutics focuses on treating brain tumors that originate in the glial cells of the brain or spinal cord, particularly in adults. This encompasses various treatment options designed to enhance the quality of life and extend the survival of individuals affected by malignant gliomas.
The primary subtypes of adult malignant glioma therapeutics include glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme (GBM), known for its aggressive nature, involves rapid tumor growth and the infiltration of neighboring brain tissue, typically without distant organ metastasis. Therapeutic interventions in this domain encompass chemotherapy, targeted therapy, radiotherapy, and other modalities. These treatments are administered in various healthcare settings, including hospitals, specialty clinics, and cancer and radiation therapy centers.
The adult malignant glioma therapeutics market research report is one of a series of new reports from The Business Research Company that provides adult malignant glioma therapeutics market statistics, including adult malignant glioma therapeutics industry global market size, regional shares, competitors with a adult malignant glioma therapeutics market share, detailed adult malignant glioma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the adult malignant glioma therapeutics industry. This adult malignant glioma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The adult malignant glioma therapeutics market size has grown rapidly in recent years. It will grow from $2.25 billion in 2024 to $2.48 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increased incidence rates, patient advocacy initiatives, personalized medicine approaches.
The adult malignant glioma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.55 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to immunotherapy advancements, targeted therapies, biomarker discoveries, liquid biopsy applications, expanded access programs. Major trends in the forecast period include patient-centric drug development, fast-track and breakthrough designation, advances in drug delivery systems, collaborative research initiative, integration of artificial intelligence.
The upward trajectory in brain tumor cases is anticipated to be a significant driver in propelling the growth of the adult malignant glioma therapeutics market. Brain tumors represent anomalous masses of tissue characterized by the abnormal proliferation and unchecked growth of cells, circumventing the usual regulatory mechanisms. Adult malignant glioma, a specific type of brain tumor, comprises cells exhibiting abnormal and uncontrolled growth patterns. Treatment for adult malignant glioma typically involves a combination of surgical procedures, radiation therapy, and chemotherapy. Illustrating this trend, as per the American Cancer Society's January 2023 report, the number of cases related to brain and nervous system cancers escalated to 24,810 in 2023, demonstrating a notable 3.85% increase from 23,890 recorded in 2020. Thus, the mounting instances of brain tumors serve as a driving force behind the expansion of the adult malignant glioma therapeutics market.
The infusion of government funding dedicated to brain cancer research is poised to significantly propel the growth trajectory of the adult malignant glioma therapeutics market moving forward. Government funding entails financial support disbursed by governmental bodies at various levels-federal, state, or local-towards initiatives, programs, projects, organizations, or individuals. The allocation of government funds for brain cancer research holds substantial promise for advancing adult malignant glioma therapeutics. This funding can significantly aid in the development of innovative treatments, tailored drug design, focusing on pyrimidine synthesis, and expediting orphan drug approvals. For example, in June 2023, the Australian Department of Health and Aged Care initiated the Australian Brain Cancer Mission, committing a fund of $136.66 million specifically aimed at supporting brain cancer research endeavors. The primary objective of this initiative is to double survival rates and enhance the overall quality of life for brain cancer patients, including those with anaplastic astrocytoma. Consequently, government funding geared towards brain cancer research stands as a pivotal driver propelling the adult malignant glioma therapeutics market.
Leading companies within the adult malignant glioma therapeutics market are actively engaged in the development of innovative products, notably small molecule targeted degraders, aimed at providing enhanced and dependable customer service. Small-molecule targeted degraders represent a class of drugs employing small molecules to induce the degradation of specific proteins by targeting both the protein of interest (POI) and an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a precision oncology company based in Sweden, attained orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17 designed to treat glioblastoma (GBM). BEA-17 functions as a small-molecule targeted degrader targeting the epigenetic enzyme LSD1 and its co-factor CoREST, implicated in the pathogenesis of various cancers, including GBM. The drug works by degrading LSD1 and CoREST, leading to the reactivation of tumor suppressor genes and inhibiting the growth of cancer cells. This innovative approach holds promise in advancing treatment options within the adult malignant glioma therapeutics market.
In May 2024, Novartis, a Switzerland-based pharmaceutical company, acquired Mariana Oncology for $1 billion. This acquisition is intended to enhance Novartis's pipeline in radioligand therapies (RLTs) for various cancers, including potential applications for solid tumors like gliomas. Mariana Oncology, a US-based preclinical-stage biotechnology firm, focuses on developing therapeutics for gliomas.
Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan PLC, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.
North America was the largest region in the adult malignant glioma therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the adult malignant glioma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The adult malignant glioma therapeutics market consists of revenues earned by entities by providing services such as resection, subtotal resection, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The adult malignant glioma therapeutics market consists of sales of temozolomide, bevacizumab, carmustine, and monoclonal antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Adult Malignant Glioma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on adult malignant glioma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for adult malignant glioma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adult malignant glioma therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type Of Disease: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma; Other Types
- 2) By Therapy: Chemotherapy; Targeted Therapy; Radiotherapy; Other Therapies
- 3) By End-User: Hospitals; Specialty Clinics; Cancer And Radiation Therapy Centers; Other End Users
- Subsegments:
- 1) By Glioblastoma Multiforme: Standard Treatments; Experimental Therapies
- 2) By Anaplastic Astrocytoma: Chemotherapy Options; Targeted Therapies
- 3) By Anaplastic Oligodendroglioma: Radiation Therapy; Combination Therapies
- 4) By Anaplastic Oligoastrocytoma: Surgical Interventions; Adjuvant Therapies
- 5) By Other Types: Rare Gliomas; Emerging Therapies
- Companies Mentioned: Johnson & Johnson Private Limited; Pfizer Inc.; Bio-Rad Laboratories Inc.; F. Hoffmann-La Roche Ltd.; Allergan plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Adult Malignant Glioma Therapeutics Market Characteristics
3. Adult Malignant Glioma Therapeutics Market Trends And Strategies
4. Adult Malignant Glioma Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Adult Malignant Glioma Therapeutics Growth Analysis And Strategic Analysis Framework
- 5.1. Global Adult Malignant Glioma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Adult Malignant Glioma Therapeutics Market Growth Rate Analysis
- 5.4. Global Adult Malignant Glioma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Adult Malignant Glioma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Adult Malignant Glioma Therapeutics Total Addressable Market (TAM)
6. Adult Malignant Glioma Therapeutics Market Segmentation
- 6.1. Global Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Anaplastic Oligoastrocytoma
- Other Types
- 6.2. Global Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy
- Targeted Therapy
- Radiotherapy
- Other Therapies
- 6.3. Global Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Cancer And Radiation Therapy Centers
- Other End Users
- 6.4. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Glioblastoma Multiforme, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Standard Treatments
- Experimental Therapies
- 6.5. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Anaplastic Astrocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy Options
- Targeted Therapies
- 6.6. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Anaplastic Oligodendroglioma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Radiation Therapy
- Combination Therapies
- 6.7. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Anaplastic Oligoastrocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Surgical Interventions
- Adjuvant Therapies
- 6.8. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Rare Gliomas
- Emerging Therapies
7. Adult Malignant Glioma Therapeutics Market Regional And Country Analysis
- 7.1. Global Adult Malignant Glioma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Adult Malignant Glioma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Adult Malignant Glioma Therapeutics Market
- 8.1. Asia-Pacific Adult Malignant Glioma Therapeutics Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Adult Malignant Glioma Therapeutics Market
- 9.1. China Adult Malignant Glioma Therapeutics Market Overview
- 9.2. China Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Adult Malignant Glioma Therapeutics Market
- 10.1. India Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Adult Malignant Glioma Therapeutics Market
- 11.1. Japan Adult Malignant Glioma Therapeutics Market Overview
- 11.2. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Adult Malignant Glioma Therapeutics Market
- 12.1. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Adult Malignant Glioma Therapeutics Market
- 13.1. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Adult Malignant Glioma Therapeutics Market
- 14.1. South Korea Adult Malignant Glioma Therapeutics Market Overview
- 14.2. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Adult Malignant Glioma Therapeutics Market
- 15.1. Western Europe Adult Malignant Glioma Therapeutics Market Overview
- 15.2. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Adult Malignant Glioma Therapeutics Market
- 16.1. UK Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Adult Malignant Glioma Therapeutics Market
- 17.1. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Adult Malignant Glioma Therapeutics Market
- 18.1. France Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Adult Malignant Glioma Therapeutics Market
- 19.1. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Adult Malignant Glioma Therapeutics Market
- 20.1. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Adult Malignant Glioma Therapeutics Market
- 21.1. Eastern Europe Adult Malignant Glioma Therapeutics Market Overview
- 21.2. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Adult Malignant Glioma Therapeutics Market
- 22.1. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Adult Malignant Glioma Therapeutics Market
- 23.1. North America Adult Malignant Glioma Therapeutics Market Overview
- 23.2. North America Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Adult Malignant Glioma Therapeutics Market
- 24.1. USA Adult Malignant Glioma Therapeutics Market Overview
- 24.2. USA Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Adult Malignant Glioma Therapeutics Market
- 25.1. Canada Adult Malignant Glioma Therapeutics Market Overview
- 25.2. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Adult Malignant Glioma Therapeutics Market
- 26.1. South America Adult Malignant Glioma Therapeutics Market Overview
- 26.2. South America Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Adult Malignant Glioma Therapeutics Market
- 27.1. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Adult Malignant Glioma Therapeutics Market
- 28.1. Middle East Adult Malignant Glioma Therapeutics Market Overview
- 28.2. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Adult Malignant Glioma Therapeutics Market
- 29.1. Africa Adult Malignant Glioma Therapeutics Market Overview
- 29.2. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Adult Malignant Glioma Therapeutics Market Competitive Landscape And Company Profiles
- 30.1. Adult Malignant Glioma Therapeutics Market Competitive Landscape
- 30.2. Adult Malignant Glioma Therapeutics Market Company Profiles
- 30.2.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Allergan plc Overview, Products and Services, Strategy and Financial Analysis
31. Adult Malignant Glioma Therapeutics Market Other Major And Innovative Companies
- 31.1. AbbVie Inc.
- 31.2. Novartis AG
- 31.3. Bayer AG
- 31.4. Merck & Co Inc.
- 31.5. GlaxoSmithKline plc
- 31.6. Bristol-Myers Squibb Company
- 31.7. Abbott Laboratories
- 31.8. AstraZeneca plc
- 31.9. Eli Lilly and Company
- 31.10. Amgen Inc.
- 31.11. Teva Pharmaceutical Industries Ltd.
- 31.12. GT Medical Technologies Inc.
- 31.13. Lupin Limited
- 31.14. Mylan NV
- 31.15. Sanofi SA
32. Global Adult Malignant Glioma Therapeutics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Adult Malignant Glioma Therapeutics Market
34. Recent Developments In The Adult Malignant Glioma Therapeutics Market
35. Adult Malignant Glioma Therapeutics Market High Potential Countries, Segments and Strategies
- 35.1 Adult Malignant Glioma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Adult Malignant Glioma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Adult Malignant Glioma Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
